Attributes | Values |
---|
rdf:type
| |
Description
| - In this paper, we discuss some critical parts of the World Health Organization (WHO) 2008 criteria for classification of MPNs classification, with most of the remarks limited to polycythemia vera (PV). When analyzing the major criteria, we note that there are PV patients whose erythrocytosis can only be documented by red cell mass measurements and not by hemoglobin concentration or hematocrit measurements. We discuss the reproducibility of histopathology for the diagnosis of different stages of MPNs, the existence of normal EPO levels in PV patients, the specificity of Endogenous erythroid colony (EEC) growth for PV diagnosis and our current knowledge of the cytogenetics and molecular biology of PV and other MPNs and their pathophysiology. We also analyze various prognostic morbidity (thrombosis) and mortality markers in PV - high hematocrit level, leukocytosis and percentage of cells with the JAK2V617F mutation. In essential thrombocythemia (ET), we comment on the distinction of true ET and %22early PMF%22. At the end, we briefly summarize the generally accepted new risk stratification European Leukemia Network (ELN) treatment recommendations for Ph-negative MPNs, evidence-based risk of carcinogenesis for hydroxyurea and rational recommendations for the selection of individual drugs.
- In this paper, we discuss some critical parts of the World Health Organization (WHO) 2008 criteria for classification of MPNs classification, with most of the remarks limited to polycythemia vera (PV). When analyzing the major criteria, we note that there are PV patients whose erythrocytosis can only be documented by red cell mass measurements and not by hemoglobin concentration or hematocrit measurements. We discuss the reproducibility of histopathology for the diagnosis of different stages of MPNs, the existence of normal EPO levels in PV patients, the specificity of Endogenous erythroid colony (EEC) growth for PV diagnosis and our current knowledge of the cytogenetics and molecular biology of PV and other MPNs and their pathophysiology. We also analyze various prognostic morbidity (thrombosis) and mortality markers in PV - high hematocrit level, leukocytosis and percentage of cells with the JAK2V617F mutation. In essential thrombocythemia (ET), we comment on the distinction of true ET and %22early PMF%22. At the end, we briefly summarize the generally accepted new risk stratification European Leukemia Network (ELN) treatment recommendations for Ph-negative MPNs, evidence-based risk of carcinogenesis for hydroxyurea and rational recommendations for the selection of individual drugs. (en)
|
Title
| - Comments on WHO Classification of Ph-Negative Myeloproliferative Neoplasms (MPN) and Overview of this MPN Issue
- Comments on WHO Classification of Ph-Negative Myeloproliferative Neoplasms (MPN) and Overview of this MPN Issue (en)
|
skos:prefLabel
| - Comments on WHO Classification of Ph-Negative Myeloproliferative Neoplasms (MPN) and Overview of this MPN Issue
- Comments on WHO Classification of Ph-Negative Myeloproliferative Neoplasms (MPN) and Overview of this MPN Issue (en)
|
skos:notation
| - RIV/61989592:15110/12:33140130!RIV13-MSM-15110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/12:33140130
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - primary myelofibrosis; essential thrombocythemia; polycythemia vera; myeloproliferative neoplasms (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Indrák, Karel
- Prchal, Josef
|
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |